Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma

Prospective Cohort Study for the Impact of Preoperative Glycemic Control Status Measured by HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Renal Cell Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02417194

Enrollment

238

Registered

2015-04-15

Start date

2015-04-30

Completion date

2018-04-30

Last updated

2015-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Renal Cell, Hemoglobin A1c Protein, Human, Pathology, Treatment Outcome

Keywords

Renal cell carcinoma, hemoglobin A1c protein, Pathologic outcomes, Oncological outcomes, Nephrectomy

Brief summary

The effect of preoperative glycemic control measured by HbA1c on renal cell carcinoma (RCC) outcome remains controversial. Thus, the investigators aim to examine the association of preoperative glycemic control with oncologic outcomes after radical or partial nephrectomy. The investigators will prospectively collect the relevant data including preoperative HbA1c in 238 patients of RCC patients undergoing nephrectomy. The associations between clinical variables and risk of adverse pathological features and disease recurrence will be tested using a multivariate logistic regression and multiple Cox-proportional hazards model, respectively.

Detailed description

* This is the observational study as the single institutional, prospective cohort study. The investigators prospectively collect the clinicopathological information of the patients with renal cell carcinoma (RCC) undergoing partial or radical nephrectomy. * Particularly, the investigators check the variables, including age at surgery, body mass index, sex, comorbidities, preoperative HbA1c levels, blood urea nitrogen (BUN)/creatinine levels, estimated-GFR, clinical TMN staging by CT scan, final pathological results (TMN stage, histology, and Fuhrman nuclear grade), warm ischemic time and surgical margin status (in the case of partial nephrectomy), postoperative recurrence and distant metastasis, renal function changes during follow-up periods. * The study protocol is same with routine follow-up schedule of the patients with RCC treated with nephrectomy. Typically, the investigators check the patients at 1, 3, 6, 12, 18, 24, 30 and 36 months. However, according to the patients status and preference, follow-up schedule can be changed within 3 months at specific time points. Because the present study is the observational cohort study, not intervention study, subtle changes of follow-up schedule would not affect on the primary outcomes. * Importantly, preoperative HbA1c should be checked within 1 month before operation, same as the routine preoperative laboratory tests.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Renal cell carcinoma (RCC) by image work-up such as CT scan * Clinically localized RCC * Aged over 20 years * Patients undergoing radical or partial nephrectomy

Exclusion criteria

* distant metastasis, preoperatively * preoperative targeted therapy * preoperative immunotherapy * medications affecting glucose status other than diabetes mellitus

Design outcomes

Primary

Measure	Time frame	Description
TMN stage	within 2 weeks after surgery	Pathological outcomes
Fuhrman (nuclear) grade	within 2 weeks after surgery	Pathological outcomes
Recurrence-free survival	postoperative up to 3 years	Oncological outcome: recurrence-free survival

Secondary

Measure	Time frame	Description
Postoperative renal function as assessed by estimated glomerular filtration rate (GFR)	postoperative up to 3 years	estimated-GFR

Countries

South Korea

Outcome results